CLINICAL_TRIALS
trial_result
· 2013-08-01
Clinical Trial Update: Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period [Phase 4]
Summary
Phase 4 trial update examining response to Kuvan (sapropterin dihydrochloride) in subjects with phenylketonuria over a 4-week testing period.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Phenylketonuria | Phase 4 | Status: COMPLETED | Results posted: 2013-08-01